High‐dose rate endorectal brachytherapy for rectal cancer: A state‐of‐the‐art review
Cancer Science · 2023-11 · 114 (11) · 4145-4156
DOI: 10.1111/cas.15959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 13.09.2023. Verfasst von Tian Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Peking University 3rd Hospital, Beijing, China. Hauptthemen laut MEDLINE: Brachytherapy, Rectal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Lianying Intelligent Imaging Technology Research Institute Hospital-enterprise Joint Research and Development Platform Fund, Innovation & Transfer Fund of Peking University Third Hospital.
Abstract (Originalsprache)
Rectal cancer is a common malignancy that requires multidisciplinary treatment. By utilizing the dose–response relationship in rectal cancer radiotherapy, increasing the radiotherapy dose can improve clinical complete remission rates. High‐dose rate endorectal brachytherapy (HDREBT) is a novel technique that delivers high doses of radiotherapy directly to the tumor via an endorectal applicator, sparing the adjacent normal tissues from excessive radiation exposure. HDREBT includes contact X‐ray brachytherapy and high‐dose‐rate intracavitary brachytherapy. We introduce the latest developments in applicators and imaging techniques for HDREBT in rectal cancer and summarize the current evidence on the efficacy, safety, and feasibility of HDREBT as a neoadjuvant, definitive, or palliative treatment option for all stages of rectal cancer patients. We also discuss the potential advantages and challenges of HDREBT in achieving organ preservation and improving the quality of life of rectal cancer patients. HDREBT has shown promising results in achieving high complete response rates, enabling nonoperative management, improving organ preservation rates, and providing effective palliation in rectal cancer patients. More studies are needed to optimize its dose and fractionation schemes in different clinical scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Peking University 3rd Hospital, Beijing, China.
- Peking University Health Science Center, Peking University, Beijing, China.
- Department of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
ORCID-Profile: Tian Cheng
Förderung
- Beijing Lianying Intelligent Imaging Technology Research Institute Hospital-enterprise Joint Research and Development Platform Fund
- Innovation & Transfer Fund of Peking University Third Hospital
Zitieren
APA
Cheng, T., Peng, R., Qu, A., & Wang, H. (2023). High‐dose rate endorectal brachytherapy for rectal cancer: A state‐of‐the‐art review. Cancer Science, 114(11), 4145-4156. https://doi.org/10.1111/cas.15959
Vancouver
Cheng T, Peng R, Qu A, Wang H. High‐dose rate endorectal brachytherapy for rectal cancer: A state‐of‐the‐art review. Cancer Science. 2023;114(11):4145-4156. doi:10.1111/cas.15959
BibTeX
@article{Cheng2023,
author = {Cheng, Tian and Peng, Ran and Qu, Ang and Wang, Hao},
title = {High‐dose rate endorectal brachytherapy for rectal cancer: A state‐of‐the‐art review},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {11},
pages = {4145--4156},
doi = {10.1111/cas.15959}
}
EUVIMED